Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Ferric Carboxymaltose-mediated Methemoglobinemia

Author(s): Muhammet Özbilen*, Şeyda Tuba Savrun, Ali Aygün and Yasemin Kaya

Volume 19, Issue 1, 2024

Published on: 03 March, 2023

Page: [134 - 137] Pages: 4

DOI: 10.2174/1574886318666230213111038

Price: $65

Abstract

Background: Methemoglobinemia is a life-threatening disorder, with levels above 1 percent considered abnormal and typically resulting from drug or toxic substance exposure.

Case Presentation: In this study, we describe a case of a 43-year-old woman with a long-standing complaint of fatigue. Iron deficiency anemia was diagnosed based on the blood test findings of hemoglobin of 101 g/L, mean red blood cell volume of 75 fL, ferritin of 2.81 ug/L, transferrin saturation of 4.3 percent, and C-reactive protein of 0.6 mg/L. As a preferred treatment option, 1000 mg ferric carboxymaltose on two distinct days was preferred. After administering the first dose of the medication, we noticed incidentally that methemoglobin levels increased to 2.3%. When venous blood gas was repeated before and after administration of the second dose of the drug, methemoglobin levels were found to be 0.8% and 1.8%, respectively. There was no change in vital signs in both two dosages, and she only suffered a temporary sore throat. Her anemia improved with intravenous iron therapy, and she is currently being followed in our clinic.

Conclusion: No case or research reporting an increase in methemoglobin levels following oral and/or intravenous treatment to patients with iron deficiency anemia has been found in the literature. Therefore, this is the first contribution to the existing literature.

« Previous Next »
[1]
Ludlow JT, Wilkerson RG, Nappe TM. Methemoglobinemia. StatPearls. Treasure Island, FL: StatPearls Publishing 2022.
[2]
Ziabari Y. Local Anesthetics.Plastic Surgery: Principles and Practice. Elsevier Inc: Amsterdam, 2022; pp. 37-48.
[http://dx.doi.org/10.1016/B978-0-323-65381-7.00004-6]
[3]
Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: Etiology, pharmacology, and clinical management. Ann Emerg Med 1999; 34(5): 646-56.
[http://dx.doi.org/10.1016/S0196-0644(99)70167-8] [PMID: 10533013]
[4]
Abouelezz K F. Methemoglobinemia: Practice Essentials, Background, Pathophysiology. 2022. Available from: https://emedicine.medscape.com/article/204178-overview#a4
[5]
Wills BK, Cumpston KL, Downs JW, Rose SR. Causative agents in clinically significant methemoglobinemia: A national poison data system study. Am J Ther 2021; 28(5): e548-51.
[http://dx.doi.org/10.1097/MJT.0000000000001277] [PMID: 33416248]
[6]
Shin HW, Go DY, Lee SW, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients. Medicine 2021; 100(20): e24571.
[http://dx.doi.org/10.1097/MD.0000000000024571] [PMID: 34011020]
[7]
Hald K, Lieng M. Assessment of periodic blood loss: Interindividual and intraindividual variations of pictorial blood loss assessment chart registrations. J Minim Invasive Gynecol 2014; 21(4): 662-8.
[http://dx.doi.org/10.1016/j.jmig.2014.01.015] [PMID: 24469275]
[8]
Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside a systematic review and meta‐analysis. Br J Clin Pharmacol 2021; 87(5): 2256-73.
[http://dx.doi.org/10.1111/bcp.14643] [PMID: 33188534]
[9]
Yuen H-W, Becker W. Iron Toxicity StatPearls. Treasure Island, FL: StatPearls Publishing 2022.
[10]
Iron Toxicity Workup: Laboratory Studies, Imaging Studies. 2022. Available from: https://emedicine.medscape.com/article/815213-workup 2022.
[11]
Ohira Y, Simpson DR, Edgerton VR, Gardner GW, Senewiratne B. Characteristics of blood gas in response to iron treatment and exercise in iron-deficient and anemic subjects. J Nutr Sci Vitaminol 1983; 29(2): 129-39.
[http://dx.doi.org/10.3177/jnsv.29.129] [PMID: 6411878]
[12]
Iolascon A, Bianchi P, Andolfo I, et al. Recommendations for diagnosis and treatment of methemoglobinemia. Am J Hematol 2021; 96(12): 1666-78.
[http://dx.doi.org/10.1002/ajh.26340] [PMID: 34467556]
[13]
Zimmerman JJ. Toxidromes and Their Treatment. Fuhrman and Zimmerman’s Pediatric Critical Care. Elsevier: Amsterdam, 2022; pp. 1500.
[14]
Umbreit J. Methemoglobin It’s not just blue: A concise review. Am J Hematol 2007; 82(2): 134-44.
[http://dx.doi.org/10.1002/ajh.20738] [PMID: 16986127]
[15]
Ferinject. 2022. Available from: https://www.medcines.org.uk/emc/product/5910/smpc#gref
[16]
Holden HF. Methaemoglobin, a Spectrophotometric study. Aust J Exp Biol Med Sci 1936; 14(4): 291-304.
[http://dx.doi.org/10.1038/icb.1936.27]
[17]
Ohki N, Kimura T, Ogata Y. The reduction of methemoglobin in neo red cell. Artif Cells Blood Substit Immobil Biotechnol 1998; 26(5-6): 477-85.
[http://dx.doi.org/10.3109/10731199809117468] [PMID: 9844714]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy